Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney

被引:110
作者
Zaier, Zoulikha M. [1 ]
Eloranta, Jyrki J. [1 ]
Stieger, Bruno [1 ]
Kullak-Ublick, Gerd A. [1 ]
机构
[1] Univ Zurich Hosp, Dept Internal Med, Div Clin Pharmacol & Toxicol, CH-8091 Zurich, Switzerland
关键词
drug transporter; estrone-3-sulfate; farnesoid X receptor; organic anion transporter protein; organic anion-transporting polypeptide; organic cation transporter; PEPT1; pharmacokinetics; SNP; statin;
D O I
10.2217/14622416.9.5.597
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
The role of carrier-mediated transport in determining the pharmacokinetics of drugs has become increasingly evident with the discovery of genetic variants that affect expression and/or function of a given drug transporter. Drug transporters are expressed at numerous epithelial barriers, such as intestinal epithelial cells, hepatocytes, renal tubular cells and at the blood-brain barrier. Several recent studies have associated alterations in substrate uptake with the presence of SNPs. Here, we summarize the current knowledge on the functional and phenotypic consequences of genetic variation in intestinally, hepatically and renally expressed members of the organic anion-transporting polypeptide family (OATPs; SLC21/SLCO family), the organic anion and organic cation transporters (OATs/OCTs; SLC22 family) and the peptide transporter-1 (PEPT1; SLC15 family).
引用
收藏
页码:597 / 624
页数:28
相关论文
共 109 条
[1]
LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers [J].
Abe, T ;
Unno, M ;
Onogawa, T ;
Tokui, T ;
Kondo, TN ;
Nakagomi, R ;
Adachi, H ;
Fujiwara, K ;
Okabe, M ;
Suzuki, T ;
Nunoki, K ;
Sato, E ;
Kakyo, M ;
Nishio, T ;
Sugita, J ;
Asano, N ;
Tanemoto, M ;
Seki, M ;
Date, F ;
Ono, K ;
Kondo, Y ;
Shiiba, K ;
Suzuki, M ;
Ohtani, H ;
Shimosegawa, T ;
Iinuma, K ;
Nagura, H ;
Ito, S ;
Matsuno, S .
GASTROENTEROLOGY, 2001, 120 (07) :1689-1699
[2]
Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1 [J].
Abe, T ;
Kakyo, M ;
Tokui, T ;
Nakagomi, R ;
Nishio, T ;
Nakai, D ;
Nomura, H ;
Unno, M ;
Suzuki, M ;
Naitoh, T ;
Matsuno, S ;
Yawo, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (24) :17159-17163
[3]
Genetic variants of the human dipeptide transporter PEPT1 [J].
Anderle, P ;
Nielsen, CU ;
Pinsonneault, J ;
Krog, PL ;
Brodin, B ;
Sadée, W .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 316 (02) :636-646
[4]
Organic anion transporter family: Current knowledge [J].
Anzai, Naohiko ;
Kanai, Yoshikatsu ;
Endou, Hitoshi .
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 100 (05) :411-426
[5]
Human renal organic anion transporter 1-dependent uptake and toxicity of mercuric-thiol conjugates in Madin-Darby canine kidney cells [J].
Aslamkhan, AG ;
Han, YH ;
Yang, XP ;
Zalups, RK ;
Pritchard, JB .
MOLECULAR PHARMACOLOGY, 2003, 63 (03) :590-596
[6]
Human organic anion transporters mediate the transport of tetracycline [J].
Babu, E ;
Takeda, M ;
Narikawa, S ;
Kobayashi, Y ;
Yamamoto, T ;
Cha, SH ;
Sekine, T ;
Sakthisekaran, D ;
Endou, H .
JAPANESE JOURNAL OF PHARMACOLOGY, 2002, 88 (01) :69-76
[7]
Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6) [J].
Bleasby, K ;
Hall, LA ;
Perry, JL ;
Mohrenweiser, HW ;
Pritchard, JB .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 314 (02) :923-931
[8]
Influence of proton and essential histidyl residues on the transport kinetics of the H+/peptide cotransport systems in intestine (PEPT 1) and kidney (PEPT 2) [J].
Brandsch, M ;
Brandsch, C ;
Ganapathy, ME ;
Chew, CS ;
Ganapathy, V ;
Leibach, FH .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1997, 1324 (02) :251-262
[9]
Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs [J].
Cascorbi, Ingolf .
PHARMACOLOGY & THERAPEUTICS, 2006, 112 (02) :457-473
[10]
The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability [J].
Chan, LMS ;
Lowes, S ;
Hirst, BH .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 21 (01) :25-51